Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 -0.32%53 Altman Z2-Score is 27.05 as of Aug. 02, 2026, which is 100% above its 10-year median of 13.55. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Amcad Biomed ranks better than 98.45% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Amcad Biomed has a Altman Z2-Score of 27.05, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Amcad Biomed's Altman Z2-Score or its related term are showing as below:
ROCO:4188'
s Altman Z2-Score Range Over the Past 10 Years
Min: 8.74 Med: 13.55 Max: 27.05
Current: 27.05
During the past 13 years, Amcad Biomed's highest Altman Z2-Score was 27.05. The lowest was 8.74. And the median was 13.55.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Amcad Biomed Altman Z2-Score Related Terms
Amcad Biomed Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: Altman Z2-Score Comparison
For the Medical Devices subindustry, Amcad Biomed's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Amcad Biomed's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.6293
+
3.26
*
-0.4064
+
6.72
*
-0.1145
+
1.05
*
23.8289
=
27.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Amcad Biomed (ROCO:4188) has a Altman Z2-Score of 27.05 as of Aug. 02, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Amcad Biomed and its competitors. This is 100% above median its historical median of 13.55. Over the past decade, Amcad Biomed's Altman Z2-Score has ranged from 8.74 to 27.05. According to the industry distribution chart, Amcad Biomed ranks #13 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 1.5%.
Is Amcad Biomed's Altman Z2-Score too high?
Amcad Biomed's current Altman Z2-Score of 27.05 is 100% above median its 10-year median of 13.55. Over the past 10 years, this metric has ranged from a low of 8.74 to a high of 27.05. The Medical Devices & Instruments industry median Altman Z2-Score is 3.45. Amcad Biomed's value of 27.05 is 684.1% above this industry median. Based on the distribution chart, Amcad Biomed ranks #13 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #13 out of 840 companies for Altman Z2-Score. This places Amcad Biomed in the top 2% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.45. Amcad Biomed's value of 27.05 is 684.1% above this benchmark. Historically, Amcad Biomed's own Altman Z2-Score has ranged from 8.74 to 27.05 over the past decade. While the company's 10-year median is 13.55 vs. the industry median of 3.45, Amcad Biomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.45, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amcad Biomed's current Altman Z2-Score of 27.05 is 684.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Altman Z2-Score is 27.05, which is 100% above median its own 10-year median of 13.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Altman Z2-Score is 27.05, which is 100% above median its 10-year median of 13.55 and 684.1% above the Medical Devices & Instruments industry median of 3.45. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Altman Z2-Score is 27.05 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
Altman Z2-Score: 27.05 (100% above median its 10-year median of 13.55)
GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
Industry Position: 684.1% above the Medical Devices & Instruments median (#13 of 840)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score
Get the complete analysis for ROCO:4188
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
